Should I Switch Sulfonylureas to Insulin in MODY Pregnancy?

If you have HNF1A- or HNF4A-MODY, your medical team will typically recommend transitioning from sulfonylurea pills to insulin before or during pregnancy ^[1][2]. This is not because the pills have stopped working for you ^[3]. Instead, insulin is generally preferred because it does not cross the placenta, which helps protect your baby’s development ^[4][1].

Important Safety Note: If you are planning a pregnancy or have just had a positive pregnancy test, contact your endocrinologist and maternal-fetal medicine team immediately. Do not stop or change your medication on your own. Stopping medication abruptly can cause high blood sugar, which carries its own risks for the pregnancy.

Why Specialists Recommend the Switch

Sulfonylureas work by stimulating your pancreas to produce more insulin. During pregnancy, some of these medications—most notably glyburide (also known as glibenclamide)—have been shown to cross the placenta and enter the baby’s bloodstream ^[5][1].

When the medication reaches the baby, it can overstimulate the baby’s pancreas to produce extra insulin. This can lead to two main complications:

• Macrosomia (excessive birth weight): Insulin acts as a growth-promoting hormone in a developing baby. Too much insulin can cause the baby to grow much larger than normal, which can complicate delivery ^[1].
• Neonatal Hypoglycemia (low blood sugar after birth): Because the baby is producing extra insulin in the womb, their blood sugar can drop rapidly after birth when they are no longer receiving sugar through the placenta ^[1].

The Role of Genetics in HNF4A and HNF1A

These medication risks overlap with the genetic risks of MODY. MODY is an inherited form of diabetes, and a baby has a 50% chance of inheriting the gene variant from an affected parent.

If a baby inherits the HNF4A variant, they naturally have a genetic tendency to overproduce insulin in the womb. This already increases their risk for macrosomia and persistent low blood sugar after birth ^[6][1]. Adding a sulfonylurea medication on top of this genetic tendency can further overstimulate the baby’s pancreas ^[1]. Babies who inherit the HNF1A variant may also have an increased risk for overgrowth and neonatal hypoglycemia, though the evidence for this is less established than for HNF4A ^[7].

Switching to insulin reduces the risk of adding medication-induced insulin production on top of the baby’s inherited genetic risks.

Why Insulin is the Standard Alternative

Unlike sulfonylureas, injected insulin (delivered via daily injections or an insulin pump) does not cross the placenta in clinically significant amounts ^[4][1]. It helps lower your blood sugar without directly affecting the baby’s pancreas.

Because MODY is rare, most large studies comparing insulin to sulfonylureas have been done in women with gestational diabetes. In those populations, insulin use was associated with a lower risk of excessive birth weight, respiratory distress, and neonatal intensive care admissions compared to glyburide ^[8][9]. While this is indirect evidence, specialists apply these findings to MODY pregnancies to reduce potential risks ^[1][2].

Timing the Transition and Monitoring

There is no single universal rule for exactly when to switch medications. Your specialist team will create an individualized plan based on your blood sugar patterns, the specific medication you take, and how far along you are ^[10].

• Pre-conception: Many specialists prefer switching to insulin before pregnancy so the baby is never exposed to sulfonylureas ^[1][2].
• Early Pregnancy: If your blood sugar is well-controlled on a sulfonylurea, some specialists may allow you to continue it briefly into early pregnancy and transition to insulin in the second trimester ^[1][11]. This is an area of differing medical practice, not a guarantee that early exposure is completely risk-free.

Monitoring During and After Pregnancy

• During Pregnancy: Your team may arrange serial ultrasound scans to monitor the baby’s growth ^[10]. However, ultrasounds cannot measure the baby’s insulin levels or predict exactly what their blood sugar will be after birth. Your own insulin doses will be adjusted based on your continuous glucose monitor (CGM) or fingerstick readings, not ultrasound results ^[10].
• After Delivery: Immediately after birth, the pediatric team will closely monitor the baby’s blood sugar and provide early feeding or glucose therapy if needed ^[6]. Additionally, your own insulin needs will drop rapidly after you deliver the placenta, so your team will need a plan for reducing your insulin doses or transitioning back to your sulfonylurea medication.